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ABSTRACT
Background. Recurrence patterns in stage III colon can-
cer (CC) patients according to molecular markers remain
unclear. The objective of the study was to assess recurrence
patterns according to microsatellite instability (MSI), RAS
and BRAFV600E status in stage III CC patients.
Methods. All stage III CC patients from the PETACC-8
randomized trial tested for MSI, RAS and BRAFV600E status
were included. The site and characteristics of recurrence
were analyzed according to molecular status. Survival after
recurrence (SAR) was analyzed.
Results. A total of 1650 patients were included. Recur-
rence occurred in 434 patients (26.3%). Microsatellite
stable (MSS) patients had a significantly higher recurrence
rate (27.2% vs. 18.7%, P = 0.02) with a trend to more
pulmonary recurrence (28.8% vs. 12.9%, P = 0.06) when
compared to MSI patients. MSI patients experienced more
regional lymph nodes compared to MSS (12.9% vs. 4%,
P = 0.046). In the MSS population, the recurrence rate was
significantly higher in RAS (32.2%) or BRAF (32.3%)
patients when compared to double wild-type patients
(19.9%) (p\ 0.001); no preferential site of recurrence was
observed according to RAS and BRAFV600E mutations.
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Finally, decreased SAR was observed in the case of peri-
toneal recurrence or more than two recurrence sites.
Conclusions. Microsatellite, RAS and BRAFV600E status
influences recurrence rates in stage III CC patients. How-
ever, only microsatellite status seems to be associated with
specific recurrence patterns. More than two recurrence sites
and recurrence in the peritoneum were associated with
poorer SAR.
Colon cancer (CC) is the third most common cancer
worldwide.1 When diagnosed at a localized stage, curative
management including colectomy with complete mesocolic
excision is required and fluoropyrimidine-based adjuvant
chemotherapy is proposed when nodal involvement is
observed (stage III disease).2–4 In 2004, adjuvant oxali-
platin-fluoropyrimidine combination therapy became the
worldwide standard treatment for stage III CC patients able
to receive.3 It increases the 3-year, disease-free survival
(DFS) rate and the long-term overall survival (OS) rate
compared with fluoropyrimidine alone.3
However, 50% of stage III patients are cured by surgery
alone, 20% with the addition of adjuvant chemotherapy,
and 30% will develop recurrence, which is generally fatal
within 2–3 years.2 Disease stage remains the most impor-
tant prognostic variable, but there is considerable stage-
independent prognostic variability, likely due to tumor
characteristics and biological heterogeneity.5–8 Colorectal
cancer is biologically heterogeneous and two major path-
ways of colorectal carcinogenesis have been described:
chromosomal instability and, less commonly, microsatel-
lite instability (MSI), which is reported in approximately
15% of sporadic cases.5 Recent publications also show that
BRAFV600E and RAS mutations are prognostic factors and
are significantly associated with shorter DFS and OS in
stage III CC patients with microsatellite-stable (MSS)
tumors, but not in MSI tumors.6,8–10 With regard to
recurrence patterns of stage III CC patients, data analyzing
the association between the recurrence site and these
molecular markers remain poor and unclear.
The PETACC-8 trial was an open randomized, con-
trolled, multinational/multicenter European phase III study
that evaluated the efficacy of cetuximab in addition to
FOLFOX-4 for 6 months in patients with fully resected
stage III colon cancer.11 The purpose of this post hoc
analysis was to assess, in stage III colon cancer patients
derived from the PETACC-8 trial, recurrence patterns
according to MSI, RAS, and BRAFV600E status.11 We also
examined survival after recurrence (SAR) according to the
site, the number of recurring sites, and biomolecular
markers.
METHODS
Population of the Study
This study included all stage III CC patients (any T, N1
or N2, M0) from the PETACC-8 trial, (NCT00265811)
promoted by the FFCD (Fédération Francophone de
Cancérologie Digestive), with a signed informed consent
for biological sample collection and tested for MSI, RAS,
and BRAF status.11 The trial failed to demonstrate the
benefit in DFS of the addition of cetuximab to the FOL-
FOX (folinic acid [leucovorin calcium], fluorouracil, and
oxaliplatin) regimen in stage III CC.11 The PETACC-8 trial
was performed in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines and
approved by the appropriate Ethics Committees.
Follow-up
For patient follow-up, a standard radiological evaluation
was made at randomization and during adjuvant treatment
and then every 6 months during the first 5 years of follow-
up and then annually, including at least chest X-ray and
abdominal US, but more generally a chest-abdomen-pelvis
CT scan. Neurological explorations were guided by the
clinical exam. Diagnosis of recurrence was established
either histologically or by imaging. The PETACC-8 data-
base used in this study was locked on October 27, 2016.
Data Extraction
Demographics, cancer history, pathological, clinical,
and biological parameters were prospectively collected at
the time of randomization, as were efficacy outcomes
(DFS, OS, and SAR).
Mismatch Repair Status
Mismatch repair (MMR) tumor status was determined
by immunohistochemical analysis (IHC) or by MSI testing
when IHC was indeterminate. MSI phenotype tumors were
defined as exhibiting the loss of expression of one or more
MMR proteins by IHC or exhibiting high-level tumor DNA
MSI on MSI testing. MSS phenotype tumors were defined
by normal MMR protein expression in IHC or MSS or low-
level MSI status on MSI testing. Mismatch repair protein
(MLH1, MSH2, MSH6, PMS2) expression was analyzed
by IHC on tissue microarrays. Concerning MSI testing,
DNA was extracted from formalin-fixed, paraffin-embed-
ded (FFPE) tumor tissues for MSI analysis using five
monomorphic mononucleotide markers (BAT-25, BAT-26,
NR-21, NR-24, NR-27). Specimens with at least three
unstable markers were scored as highly unstable, and
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specimens with fewer than three unstable markers were
scored as stable.
RAS and BRAFV600E Status
RAS hotspot mutations (c.34G[A/p.G12S, c.34G[C/
p.G12R, c.34G[T/p.G12C, c.35G[A/p.G12D,
c.35G[C/p.G12A, c.35G[T/p.G12 V and c.38G[A
p.G13D) and the BRAFV600E mutation (c.1799T[A/
p.V600E) were detected by real-time PCR with TaqMan
probes (Applied Biosystems, Paris, France). Exons 2, 3,
and 4 of KRAS and NRAS, as well as BRAF exons 11 and
15, were sequenced with the Ampliseq colon-lung cancer
panel version 2 in the PETACC8 trial participants who
consented to translational research.
Statistical Analysis
Median (interquartile range) values and proportions
(percentage) were provided for the description of contin-
uous and categorical variables, respectively. Median and
proportions were compared using the Wilcoxon-Mann–
Whitney test and v2-test (or Fisher’s exact test, if appro-
priate), respectively.
Survival after recurrence (SAR) was defined as time
between recurrence and death from any cause and was
estimated using the Kaplan–Meier method and described
using median or rate at specific time points with their 95%
confidence intervals (95% CI). Differences between groups
of patients were analyzed with unstratified log-rank tests.
All analyses were performed using R software version
2.15.2 (R Development Core Team, Vienna, Austria; http://
www.r-project. org). P values\ 0.05 were considered
statistically significant, and all tests were two-sided.
RESULTS
Patients
Among the 2559 patients enrolled in the PETACC-8
phase III trial, between December 2005 and November
2009, 1650 patients with signed informed consent for
biological sample collection and tested for MMR, RAS and
BRAFV600E status were included (Fig. 1). In the present
study population, MSI tumors and RAS and BRAFV600E
mutations were found in 10% (166 of 1650), 45% (748 of
1650), and 7.7% (127 of 1650) of patients, respectively.
The overall median follow-up was 7.82 (95% CI,
7.69–7.91) years.
Recurrence
Recurrence occurred in 26.3% of patients of the stage III
CC patients included (434/1650). The mean time to
recurrence was 1.7 ± 1.4 years. Of the 434 patients who
experienced recurrence, 31 were MSI (7%) and 403 MSS
(93%). MSS patients (403 of 1484) had a significantly
higher recurrence rate compared with MSI patients (31 of
166) (27.2% vs. 18.7%, P = 0.02), with a trend to more
frequent pulmonary recurrence in MSS patients as com-
pared to MSI patients (28.8% vs. 12.9%, P = 0.06) (Fig. 2;
Supplementary Table 1). Conversely, the preferential site
of recurrence in the MSI group was regional lymph nodes
compared with MSS patients (12.9% vs. 4%, P = 0.046)
(Fig. 2; Supplementary Table 1).
In the MSS population, RAS and BRAFV600E mutations
were found in 50.4% (748 of 1484) and 8.6% (127 of 1484)
of patients, respectively. The recurrence rate was signifi-
cantly higher in RAS (241/748, 32.2%) and BRAFV600E (41/
127, 32.3%) patients compared with double wild-type
patients (121/609, 19.9%; P\ 0.001) (Fig. 3; Supple-
mentary Table 2). However, no preferential site of
recurrence was observed in this MSS population according
to RAS and BRAFV600E mutations (Fig. 3, Supplementary
Table 2). Concerning the RAS alterations, no significant
differences were found between KRAS and NRAS mutant
cases concerning the number and the site of recurrences.
Survival after Recurrence
In the 434 patients who experienced recurrence, the
median survival after recurrence (SAR) was 24 months
(95% CI 21.8–26.5). No significant differences in SAR
were found between MSI and MSS patients (19.4 vs.
24.2 months, HR 1.05, 95% CI 0.66–1.67, P =0.83).
In the entire recurrence population, BRAFV600E and RAS
mutations were associated with significantly poorer SAR
compared with wild-type patients (median SAR for double
wild-type: 29 months, RASmut 24 months and BRAF-
V600Emut 15.2 months; HR for BRAFV600Emut = 2.46; 95%
CI 1.72–3.53 and HR for RASmut = 1.23; 95% CI
0.96–1.59, P\ 0.0001, respectively) (Fig. 4a).
In all patients who experienced recurrence, peritoneal
recurrence was significantly associated with poorer SAR
(median SAR: 19.7 vs. 24.3 months, HR 1.79, 95% CI
1.26–2.54, P = 0.001) (Fig. 4b). A trend to a better prog-
nosis was found for lung recurrence (27.8 vs. 22.6 months,
HR 0.80, 95% CI 0.62–1.03, P = 0.08) (Fig. 4c). SAR
according to liver recurrence was not modified (HR 1.12,
95% CI 0.92–1.44, P = 0.22) (Fig. 4d).
Interestingly, the number of recurrence sites was prog-
nostic. More than two recurrence sites was associated with
poorer SAR compared with one or two sites (median SAR:
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15.2 vs. 25.9 months, HR 2.7, 95% CI 1.71–4.25,
P\ 0.0001) (Fig. 4e).
DISCUSSION
Biological molecular status in metastatic colorectal
cancer is becoming increasingly relevant; RAS, BRAFV600E,
and MSI assessments are nowadays part of our routine
practice and are recommended upfront to drive patients’
treatment in the metastatic setting.12 However, little is
known about their correlation with site-specific patterns of
recurrence in patients initially nonmetastatic.
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FIG. 2 Percentage of patients with disease recurrence according to





















































FIG. 3 Percentage of patients with disease recurrence according to
metastatic site, BRAFV600E and RAS status in the MSS population.
*p\ 0.05. BRAF mutation = BRAFV600E mutation



























































































































































































































































FIG. 4 Survival after recurrence according to molecular profile and
recurrence site. a Survival after recurrence according to RAS and
BRAFV600E status. BRAFmut = BRAFV600E mutation. b Survival
after recurrence according to peritoneal recurrence. c Survival after
recurrence according to lung recurrence. d Survival after recurrence
according to liver recurrence. e Survival after recurrence according to
number of recurrence sites
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The present study analyzed recurrence rate and site of
recurrence in 1650 stage III CC patients of the PETACC-8
trial tested for biological molecular markers. The main
findings were a higher recurrence rate in the MSS popu-
lation with the ‘‘lung’’ as a preferential site of recurrence,
as MSI patients experienced fewer recurrences with ‘‘re-
gional lymph nodes’’ as a preferential site of recurrence.
Survival after recurrence was not significantly different
between MSI and MSS patients. In the MSS population,
RAS and BRAFV600E mutations were associated with sig-
nificantly higher recurrence rates, but no preferential sites
of recurrence according to these mutations were observed.
Finally, peritoneal recurrence and more than two recur-
rence sites were associated with poorer SAR.
Concerning the impact of MMR status on the site of
recurrence, Prasanna et al.13 recently published a retro-
spective study of two Australian databases including more
than 5000 stage IV CC patients and analyzed the associa-
tion between tumor biological characteristics (including
MSI status) and the site of metastatic lesions. They found
that liver-only metastases were less frequent in MSI
patients (relative risk [RR] = 0.7, P = 0.01) but that MSI
status was not associated with other specific sites of
metastatic disease. In our study, MSI tumors were not
associated with a lower rate of liver recurrence but with a
higher rate of regional node metastases, a finding that has
been already reported by others.14,15 We also found a
strong trend to more lung recurrences in MSS patients,
which has, to our knowledge, not been described before.
The prognostic significance of MSI phenotype in meta-
static disease is still controversial; some studies reported
poor outcome in metastatic MSI tumors and other studies
not.7,14,16–18 Here, SAR was not significantly different
between the MSS and MSI patients after a median follow-
up exceeding 7 years (median SAR: 19.4 vs. 24.2 months,
P = 0.82). However, our study focused on recurrence pat-
terns and SAR of stage III patients and not on initially
nonresectable metastatic patients, unlike previous studies
of that topic.17
Concerning RAS status, we found no preferential site of
metastatic relapse in our population, whereas a major part
of the available literature in patients with resected stage II
and III colon cancer reports that the presence of a RAS
mutation significantly increases the rate of lung recurrence,
with HR ranging from 1.4 to 2.1.13,19–21 Interestingly,
Yaeger et al.22 described that at the time of metastasis
diagnosis, RAS mutated tumors are more likely to be
associated with lung metastasis compared with RAS wild-
type (22% vs. 13%, P\ 0.01). In our study, the rate of
lung recurrence in RAS mutant patients was slightly but not
significantly increased compared with RAS/BRAFV600E
wild-type and BRAFV600E mutant patients (29.9%, 27.3%,
26.7%, respectively, NS).
BRAFV600E mutated tumors were not statistically asso-
ciated with a specific site of recurrence in the present work.
However, we found a trend for a higher rate of peritoneal
recurrence in BRAFV600E mutant patients as compared to
RAS mutant and double wild-type patients (12.2% vs.
7.44% vs. 9.96%, respectively) as previously described in
the literature.13,14,21,23–26 These patterns of metastatic
spread have even been suggested to be responsible, at least
in part, for the poor outcomes of BRAFV600E mutant
mCRC. Here, although no significant difference was found
for peritoneal recurrence in BRAFV600E mutants, the poor
prognosis of these patients was clearly observed.
We also observed a trend to more regional node recur-
rence in double wild-type MSS patients when compared to
BRAFV600E or RAS mutated patients, although this recur-
rence pattern occurs in less than 10% of patients in all
molecular subgroups. BRAFV600E and RAS mutations were
associated with significantly poorer SAR in the entire
series compared with wild-type patients. Moreover, peri-
toneal recurrence and number of recurrence sites (more
than two) were significantly associated with poorer SAR.
These results are in line with the available literature and
confirm that a peritoneal recurrence pattern is a poor
prognostic indicator.5–9,16,21,25–27
The strengths of the present study include the analysis of
biological markers in a large, prospective collection of
tumors, from a homogenous population of stage III colon
cancer patients, treated in a randomized trial with the
standard adjuvant chemotherapy. Limitations include the
retrospective analysis of data from subgroups with limited
numbers of patients in some cases, which may preclude the
drawing of any definitive conclusions. Moreover, the
absence of data on the treatment of recurrence may impact
the SAR results.
To conclude, this large analysis of stage III colon cancer
patients tested for MSI, BRAFV600E and RAS shows that
MSS patients had more recurrence and that recurrence is
more frequent in MSS patients with RAS and BRAFV600E
mutations. Recurrence pattern analysis showed more lung
recurrence for MSS patients and more regional node
recurrence for MSI patients, but no preferential site for
disease recurrence for BRAF or RAS patients in this series.
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